Cyclooxygenase‐2 and Tumor Biology

Kanaoka, Shigeru; Takai, Tetsunari; Yoshida, Kenichi

doi:10.1016/s0065-2423(06)43002-x

Cited by 42 publications

(41 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data presented herein show the following: (1) faecal COX-2 mRNA expression is upregulated in patients with CRC, reconfirming our previous findings (Kanaoka et al, 2004(Kanaoka et al, , 2007Takai et al, 2009), (2) faecal COX-2 mRNA expression is significantly correlated with faecal B2M, CEA, and E-cad mRNA expressions that are upregulated in CRC, (3) faecal COX-2 mRNA expression is also significantly correlated with faecal expression of CD45 mRNA, which is expressed only in patients with CRC, and (4) faecal COX-2 mRNA expression is significantly correlated with tumour size and with COX-2 mRNA expression in tumour tissues, as well as with the product of tumour size and COX-2 mRNA expression in primary tumour.…”

Section: Discussionsupporting

confidence: 91%

“…However, FOBT is less sensitive for detecting proximal CRC lesions and small lesions (Morikawa et al, 2005). We previously reported that faecal COX-2 mRNA assay is useful for detecting CRC (Kanaoka et al, 2004(Kanaoka et al, , 2007Takai et al, 2009). However, the factors that contribute to faecal COX-2 mRNA expression in CRC have not been evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…We previously reported that faecal cyclooxygenase-2 (COX-2) mRNA assay is a sensitive and specific method to detect CRC and adenoma (Kanaoka et al, 2004(Kanaoka et al, , 2007Takai et al, 2009). However, factors that contribute to faecal COX-2 mRNA expression were not well evaluated.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer

et al. 2010

View full text Add to dashboard Cite

BACKGROUND : We previously reported that a faecal cyclooxygenase-2 (COX-2) mRNA assay was useful for identifying colorectal cancer (CRC). This study sought to investigate the factors that contribute to faecal COX-2 mRNA expression in subjects with CRC. METHODS: The study cohort comprised 78 patients with CRC and 36 control subjects. The expressions of COX-2, b-2-microglobulin (B2M), carcinoembryonic antigen (CEA), E-cadherin (E-cad), and CD45 mRNA in faeces and COX-2 mRNA expression in tissue were determined by quantitative real-time RT -PCR. RESULTS: The level of faecal expression of COX-2 mRNA in CRC was significantly higher than that in controls. A significant correlation was found between faecal COX-2 mRNA expression and faecal B2M, CEA, E-cad, or CD45 mRNAs, markers of exfoliated total cells, colonocytes, and leukocytes, respectively. A significant correlation was found between the expression of COX-2 mRNA in faeces and tumour surface area, COX-2 mRNA expression in primary tumour. There was no difference in faecal COX-2 mRNA expression between proximal CRC and distal CRC. CONCLUSION: COX-2 mRNA expression in faeces seems to originate from tumour lesion and to be affected by factors such as the number of exfoliated cells, exfoliation of inflammatory cells, COX-2 mRNA expression in tumour, and tumour size.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…RNA-based stool assays have been reported in several preliminary studies (17)(18)(19)(20)(21). We previously reported the usefulness of detecting cyclooxygenase 2 (COX-2) mRNA in feces to identify the patients with CRC and adenoma (20,21).…”

Section: Introductionmentioning

confidence: 99%

“…We previously reported the usefulness of detecting cyclooxygenase 2 (COX-2) mRNA in feces to identify the patients with CRC and adenoma (20,21). The overexpression of COX-2 was reported to be found in 80% to 90% of adenocarcinoma and 50% to 60% of adenomas (22,23).…”

Section: Introductionmentioning

confidence: 99%

Fecal Cyclooxygenase 2 Plus Matrix Metalloproteinase 7 mRNA Assays as a Marker for Colorectal Cancer Screening

Takai¹,

Kanaoka

Yoshida

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

We previously reported that fecal cyclooxygenase 2 (COX-2) mRNA assay, detecting COX-2 mRNA in feces, is useful for identifying subjects with colorectal cancer (CRC). To further improve the sensitivity, we evaluated the usefulness of the combination of COX-2 mRNA and matrix metalloproteinase 7 (MMP-7) mRNA assays as a marker of CRC. The study cohort included 62 patients with CRC and 29 control patients without colorectal neoplasia. RNA was isolated from routinely collected fecal samples. The expression levels of COX-2 and MMP-7 mRNAs were determined by nested reverse transcription-PCR. PCR conditions were optimized where the specificity of fecal COX-2 and MMP-7 mRNA assay result in 100%. The sensitivity of each fecal assay was 87% [95% confidence interval (95% CI), 76-94%] and 65% (95% CI, 51-76%) for CRC, respectively. The sensitivity of fecal RNA test (either marker being positive) was high for CRC (90%; 95% CI, 80-96%). The sensitivity of the fecal RNA test was also high (93%; 95% CI, 80-98%) in patients with stage I or II who are often cured by surgical resection. The fecal RNA test using COX-2 and MMP-7 mRNAs improved the sensitivity to detect CRC without decreasing the specificity. These results suggest that the fecal RNA test would be a promising approach for CRC screening, although larger clinical investigations are indicated. (Cancer Epidemiol Biomarkers Prev 2009;18(6):1888-93)

show abstract

Protein kinase CK2 promotes cancer cell viability via up‐regulation of cyclooxygenase‐2 expression and enhanced prostaglandin E2 production

Yefi

Ponce

Niechi

et al. 2011

J of Cellular Biochemistry

View full text Add to dashboard Cite

Augmented expression of protein kinase CK2 is associated with hyperproliferation and resistance to apoptosis in cancer cells. Effects of CK2 are at least partially linked to signaling via the Wnt/β-catenin pathway, which is dramatically enhanced in colon cancer. Cyclooxygenase-2 (COX-2), a Wnt/β-catenin target gene, has been associated with enhanced cancer progression and metastasis. However, the possibility that a connection may exist between CK2 and COX-2 has not been explored previously. Here we investigated changes in COX-2 expression and activity upon CK2 modulation and evaluated how these changes affected cell viability. COX-2 expression and cell viability decreased upon selective inhibition of COX-2 with SC-791 or CK2 with 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), both in human colon (HT29-ATCC, HT29-US, DLD-1) and breast (ZR-75) cancer cells, as well as in human embryonic kidney (HEK-293T) cells. On the other hand, ectopic CK2α expression promoted up-regulation of COX-2 by activating the Wnt/β-catenin pathway in HEK-293T cells. Noteworthy, over-expression of either CK2α, β-catenin or COX-2, as well as supplementation of the medium with prostaglandin E2 (PGE2), all were individually sufficient to overcome limitations in cell viability triggered by CK2 inhibition either upon addition of DMAT or over-expression of a dominant negative CK2α variant. Altogether, these findings provide new insight to the role of CK2 in cancer by up-regulating COX-2 expression and thereby PGE2 production.

show abstract

Cyclooxygenase‐2 and Tumor Biology

Cited by 42 publications

References 104 publications

Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer

Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer

Fecal Cyclooxygenase 2 Plus Matrix Metalloproteinase 7 mRNA Assays as a Marker for Colorectal Cancer Screening

Protein kinase CK2 promotes cancer cell viability via up‐regulation of cyclooxygenase‐2 expression and enhanced prostaglandin E2 production

Contact Info

Product

Resources

About